Adjunctive Eptifibatide Treatment Feasible in Peripheral Vascular Disease Intervention

Strategic Insights -

Patients undergoing percutaneous coronary intervention for peripheral vascular disease can safely benefit from adjunctive eptifibatide treatment. A single-center pilot trial conducted by K.J. Rocha-Singh and colleagues at St. John's Hospital in Springfield evaluated the safety and feasibility of eptifibatide treatment in 85 patients undergoing percutaneous transluminal angioplasty or stenting for severe claudication or critical limb ischemia. The study demonstrated that eptifibatide treatment was safe, with low rates of major bleeding and thrombocytopenia.

Key Takeaways:

  • The study involved 85 patients undergoing percutaneous transluminal angioplasty or stenting for severe claudication or critical limb ischemia.
  • Eptifibatide treatment was safe, with a low rate of major bleeding at 3.5% and thrombocytopenia at 1.2%.
  • One patient developed a postprocedure compartment syndrome requiring fasciotomy.
  • The procedure was technically successful in 100% of patients, as defined by the study's criteria.
  • The study supports further investigation into the potential efficacy of glycoprotein IIb-IIIa inhibitors in peripheral vascular disease interventions.
  • K.J. Rocha-Singh and colleagues published the study in Catheterization and Cardiovascular Interventions in 2005.

Statistics:

  • 85 patients underwent percutaneous transluminal angioplasty or stenting for severe claudication or critical limb ischemia.
  • Eptifibatide treatment was associated with a 3.5% rate of major bleeding.
  • Thrombocytopenia occurred in 1.2% of patients receiving eptifibatide treatment.
  • One patient developed a postprocedure compartment syndrome requiring fasciotomy.

Sources:

  • Rocha-Singh, K.J., et al. (2005). Glycoprotein IIb-IIIa receptor inhibition with eptifibatide in percutaneous intervention for symptomatic peripheral vascular disease: The CIRCULATE pilot trial. Catheter Cardiovasc Interv, 66(4), 470-473.